Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) |
|
Price: $2.3600
$0.01
0.426%
|
Day's High:
| $2.44
| Week Perf:
| 0.43 %
|
Day's Low: |
$ 2.33 |
30 Day Perf: |
-17.48 % |
Volume (M): |
13 |
52 Wk High: |
$ 6.75 |
Volume (M$): |
$ 31 |
52 Wk Avg: |
$3.81 |
Open: |
$2.42 |
52 Wk Low: |
$2.08 |
|
|
Market Capitalization (Millions $) |
24 |
Shares
Outstanding (Millions) |
10 |
Employees |
11 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-28 |
Cash Flow (TTM) (Millions $) |
-4 |
Capital Exp. (TTM) (Millions $) |
0 |
Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of neurological and neuromuscular diseases. The company is dedicated to addressing unmet medical needs and improving the lives of patients suffering from debilitating conditions. Neurobo Pharmaceuticals is known for its research and development efforts in neurology, where it aims to discover and develop innovative drugs that can potentially provide therapeutic benefits to patients. The company's pipeline includes candidates for conditions such as diabetic neuropathy, Alzheimer's disease, and neurodegenerative disorders. Neurobo Pharmaceuticals is committed to advancing its drug candidates through clinical trials and regulatory processes to ultimately deliver effective treatments to patients in need.
Company Address: 545 Concord Avenue, Suite 210 Cambridge, 2138 MA
Company Phone Number: 702-9600 Stock Exchange / Ticker: NASDAQ NRBO
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Neurobo Pharmaceuticals Inc
The Major Pharmaceutical Preparations industry has been closely watched during the earnings season of January to March 2024. Among the companies that have disclosed their results, Neurobo Pharmaceuticals Inc (NRBO) stands out with its reported operating loss and the concerns raised by analysts regarding its revenue potential. NRBO recently reported an operating loss of -$6.881 million for the most recent fiscal period. This represents a significant deterioration compared to the operating loss of -$2.52 million in the first quarter of 2023. However, what is catching the attention of analysts is the company's ability to generate revenue in the future.
|
Neurobo Pharmaceuticals Inc
he midst of a challenging October to December 2023 reporting season, Neurobo Pharmaceuticals Inc (NRBO) has managed to deliver some encouraging news to investors. Despite expectations of no adjustments at the top-line, the company's operating loss for this period amounted to $-5.667 million. While this figure might raise concerns under different circumstances, it signifies a significant improvement compared to the corresponding period the previous year, which reported an operating loss of $-10.43 million. This positive development at Neurobo Pharmaceuticals Inc, a major player in the field of Pharmaceutical Preparations, has instilled confidence in market observers. The company's ability to reduce its deficit per share from $-43.44 in the preceding fiscal year to $-2.46, represents a remarkable turnaround. Additionally, Neurobo Pharmaceuticals Inc recorded revenue of $0.00 million for the fiscal 12 Months 2023, a small indication of their ongoing efforts towards establishing prosperous revenue streams.
|
Neurobo Pharmaceuticals Inc
As the reporting cycle for the July to September 2023 quarter progresses, the financial performance of various companies is being closely monitored. Among them, Neurobo Pharmaceuticals Inc, a prominent player in the Major Pharmaceutical Preparations industry, recently disclosed an operating shortfall of $-3.893 million for the third quarter of 2023. While specific revenue figures have not been released yet, it is imperative to analyze Neurobo Pharmaceuticals' previous financial records to gain a contextual understanding of current top-line performance. Operating Shortfalls and Context: Examining the operating shortfall of $-3.104 million recorded by Neurobo Pharmaceuticals in the third quarter of 2022 offers a basis for comparison. Although the company experienced a deficit during that period, it is not uncommon for businesses to encounter challenging periods on their path towards generating significant revenue streams. Unfortunately, the financial period ending on September 30, 2023, has presented further obstacles, resulting in an extended operating shortfall of $-3.818 million.
|
Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals Inc is a pharmaceutical company that recently reported its second quarter results for 2023. The company experienced an operating loss of $-3.806 million during this period and did not generate any revenue. This article will provide an extensive overview of Neurobo Pharmaceuticals Inc, its financial performance, and its current standing in the market. The company's financial report for the second quarter of 2023 showed a decrease in operating loss compared to the same period in 2022. In 2022, Neurobo Pharmaceuticals Inc reported an operating loss of $-3.219 million, indicating an improvement in the company's bottom-line. This positive development is a significant conclusion from the fiscal interval ending June 30, 2023. The shortfall in the second quarter of 2023 was $-0.734 million, significantly lower than the $-3.303 million reported in the second quarter of 2022.
|
Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals Inc, a pioneering pharmaceutical research company, recently announced its financial results for the 12 months ending in the first quarter of 2023. Unfortunately, the figures were not as positive as the company had hoped for, with a cumulative net loss of $-14 million, resulting in a negative return on equity (ROE) of -96.06%. Furthermore, looking at the performance within the Major Pharmaceutical Preparations industry, Neurobo Pharmaceuticals Inc was ranked below 181 other companies with a higher return on equity. These figures are certainly concerning for investors who have placed their faith in the company's research capabilities.
|
Per Share |
Current |
Earnings (TTM) |
-4.25 $ |
Revenues (TTM) |
-
|
Cash Flow (TTM) |
- |
Cash |
2.12 $
|
Book Value |
1.27 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-4.25 $
|
Revenues (TTM) |
- |
Cash Flow (TTM) |
- |
Cash |
2.12 $
|
Book Value |
1.27 $ |
Dividend (TTM) |
0 $ |
|
|
|
|